These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9014200)

  • 1. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H; Hansen TS; Brøsen K
    Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H; Nielsen KK; Brøsen K
    Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Skjelbo E; Brøsen K; Hallas J; Gram LF
    Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
    Brøsen K; Hansen JG; Nielsen KK; Sindrup SH; Gram LF
    Eur J Clin Pharmacol; 1993; 44(4):349-55. PubMed ID: 8513845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K; Gram LF
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 genotype determination in the Danish population.
    Brøsen K; Nielsen PN; Brusgaard K; Gram LF; Skjødt K
    Eur J Clin Pharmacol; 1994; 47(3):221-5. PubMed ID: 7867674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K; Otton SV; Gram LF
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
    Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
    J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
    Skjelbo E; Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
    Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
    Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
    Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
    Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
    Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
    Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
    Halling J; Weihe P; Brosen K
    Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.
    Koyama E; Sohn DR; Shin SG; Chiba K; Shin JG; Kim YH; Echizen H; Ishizaki T
    J Pharmacol Exp Ther; 1994 Nov; 271(2):860-7. PubMed ID: 7965806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.